Pure Biologics Spólka Akcyjna (WAR:PUR) — Market Cap & Net Worth
Market Cap & Net Worth: Pure Biologics Spólka Akcyjna (PUR)
Pure Biologics Spólka Akcyjna (WAR:PUR) has a market capitalization of $8.33 Million (zł30.25 Million) as of September 24, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #27602 globally and #301 in its home market, demonstrating a -11.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pure Biologics Spólka Akcyjna's stock price zł2.67 by its total outstanding shares 11330249 (11.33 Million). Also see PUR asset base for a full breakdown of the balance sheet.
Pure Biologics Spólka Akcyjna Market Cap History: 2018 to 2026
Pure Biologics Spólka Akcyjna's market capitalization history from 2018 to 2026. Data shows change from $63.30 Million to $8.33 Million (-24.22% CAGR). Also see PUR cash flow metrics for how efficiently the company converts equity into cash flow.
Pure Biologics Spólka Akcyjna Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pure Biologics Spólka Akcyjna's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Pure Biologics Spólka Akcyjna stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
414.89x
Pure Biologics Spólka Akcyjna's market cap is 414.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $63.30 Million | $9.53 Million | -$689.34K | 6.64x | N/A |
| 2019 | $106.33 Million | $16.75 Million | -$4.70 Million | 6.35x | N/A |
| 2020 | $347.68 Million | $572.00K | -$12.11 Million | 607.84x | N/A |
| 2021 | $242.60 Million | $254.00K | -$13.07 Million | 955.12x | N/A |
| 2022 | $71.72 Million | $662.00K | -$26.37 Million | 108.34x | N/A |
| 2023 | $39.41 Million | $95.00K | -$35.69 Million | 414.89x | N/A |
Competitor Companies of PUR by Market Capitalization
Companies near Pure Biologics Spólka Akcyjna in the global market cap rankings as of September 24, 2026. Review Pure Biologics Spólka Akcyjna tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pure Biologics Spólka Akcyjna by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Pure Biologics Spólka Akcyjna Historical Marketcap From 2018 to 2026
Between 2018 and today, Pure Biologics Spólka Akcyjna's market cap moved from $63.30 Million to $ 8.33 Million, with a yearly change of -24.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł8.33 Million | -25.04% |
| 2025 | zł11.11 Million | -79.29% |
| 2024 | zł53.63 Million | +36.08% |
| 2023 | zł39.41 Million | -45.04% |
| 2022 | zł71.72 Million | -70.44% |
| 2021 | zł242.60 Million | -30.22% |
| 2020 | zł347.68 Million | +226.98% |
| 2019 | zł106.33 Million | +67.98% |
| 2018 | zł63.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Pure Biologics Spólka Akcyjna was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.33 Million USD |
| MoneyControl | $8.33 Million USD |
| MarketWatch | $8.33 Million USD |
| marketcap.company | $8.33 Million USD |
| Reuters | $8.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more